Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics
New products on world’s medical product marketplace:

Advanced Instruments Appoints New CEO

By Labmedica International staff writers
Posted on 17 May 2017
Print article
Image: Advanced Instruments announced the appointment of Byron Selman as Chief Executive Officer (Photo courtesy of Shutterstock).
Image: Advanced Instruments announced the appointment of Byron Selman as Chief Executive Officer (Photo courtesy of Shutterstock).
Advanced Instruments, LLC, which designs, manufactures, and markets instrumentation and associated consumables for clinical, pharmaceutical, biotechnology, microbiology and dairy laboratories, has announced the appointment of Byron Selman as Chief Executive Officer. Mr. Selman replaces John Coughlin, who served as CEO of Advanced Instruments for over 16 years, and will continue in his retirement as a non-executive Member of the Board.

Mr. Selman brings with him a broad range of experience across multiple functional disciplines including sales, marketing, business development, engineering, operations, and general management. He joins Advanced Instruments after serving as President of Global Markets with Haemonetics Corporation, prior to which he spent over 20 years with Pall Corporation in various executive level and general management positions. Selman holds a Bachelor of Science degree in Mechanical Engineering from Case Western Reserve University, and a Master of Business Administration degree from the Frank G. Zarb School of Business at Hofstra University.

“We are excited to have Byron join Advanced Instruments,” said Craig Majernik, Managing Director at Windjammer Capital Investors, which acquired the company in October 2016. “His proven leadership abilities and demonstrated record of success position him well to lead the execution of the company’s organic and acquisition growth strategy.”

Selman said, “Advanced Instruments represents a unique opportunity, given its well-respected brand, technical know-how, and channels to market. I am encouraged by the multiple avenues available to the company to enhance and expand its well-established platform in the clinical diagnostic and biopharmaceutical tools markets.”


Print article

Channels

Copyright © 2000-2017 Globetech Media. All rights reserved.